![]() |
产地 | 中国 |
品牌 | 爱必信(absin) |
货号 | abs812152 |
用途 | 见爱必信官网 |
英文名称 | 见爱必信官网 |
包装规格 | 5mg,5mg,5mg,25mg,25mg,25mg,50mg,50mg,50mg |
纯度 | 98% min% |
CAS编号 | 779353-01-4 |
别名 | SCH 727965; SCH727965; SCH-727965; PS-095760 |
是否进口 | 否 |
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:Dinaciclib (SCH727965) 产品别名:见爱必信官网 英文别名:Dinaciclib (SCH727965) 靶点:CDK CAS:779353-01-4 纯度:98% min 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述: Dinaciclib (SCH727965)是一种新型有效的CDK抑制剂,作用于CDK2,CDK5,CDK1和CDK9,无细胞试验中IC50分别为1 nM,1 nM,3 nM和4 nM。它也会阻断胸甘(dThd) DNA整合。 溶解性:DMSO 26 mg/mL (65.57 mM) 体外研究:
Dinaciclib is also a potent DNA replication inhibitor that blocks thymidine (dThd) DNA incorporation in A2780 cells with IC50 of 4 nM. Dinaciclib strongly suppresses phosphorylation of Rb on Ser 807/811 at concentrations >6.25 nM, which is in agreement with the observation that 4 nM concentrations are required for 50% inhibition of dThd DNA incorporation in the same cell model. Significantly, complete suppression of Rb phosphorylation is correlated with the onset of apoptosis, as indicated by the appearance of the p85 PARP cleavage product in cells exposed to >6.25 nM Dinaciclib. Dinaciclib is active against a broad spectrum of human tumor cell lines. Addition of Dinaciclib during hydroxyurea exposure also suppresses accumulation of γ-H2AX, in a dose-dependent manner. Dinaciclib inhibits melanoma cell proliferation, and drives melanoma cells into massive apoptosis. Dinaciclib induces the apoptosis of several osteosarcoma cell lines including those resistant to doxorubicin and dasatinib. Dinaciclib attenuates the phosphorylation of RNAP II at serine 2 and the phosphorylation of the CDK inhibitor p27Kip1 at threonine 187. Reductions in phosphorylation activity occurrs at 12 - 40 nM Dinaciclib (4 to 16 hours post-Dinaciclib addition). Dinaciclib also reduces the phosphorylation of Rb at serine 807/811. Dinaciclib induces the apoptosis of mock- and p53-depleted U2OS cells to a similar extent. 体内研究:Dinaciclib i.p. administration at 8, 16, 32, and 48 mg/kg daily for 10 days results in tumor inhibition by 70%, 70%, 89%, and 96%, respectively. Dinaciclib MED (minimum effective dose) appears to be
产品信息订购:
|